Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    50.0%

    Based on 1 completed trials

    Completion Rate
    50%(1/2)
    Active Trials
    0(0%)
    Results Posted
    0%(0 trials)
    Terminated
    1(50%)

    Phase Distribution

    Phase 2
    1
    50%
    Phase 3
    1
    50%

    Phase Distribution

    0

    Early Stage

    1

    Mid Stage

    1

    Late Stage

    Phase Distribution2 total trials
    Phase 2Efficacy & side effects
    1(50.0%)
    Phase 3Large-scale testing
    1(50.0%)

    Highest Phase Reached

    Phase 3

    Trial Status & Enrollment

    Completion Rate

    50.0%

    1 of 2 finished

    Non-Completion Rate

    50.0%

    1 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    2

    all time

    Status Distribution
    Completed(1)
    Terminated(1)

    Detailed Status

    Completed1
    Terminated1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    2
    Active
    0
    Success Rate
    50.0%
    Most Advanced
    Phase 3

    Trials by Phase

    Phase 21 (50.0%)
    Phase 31 (50.0%)

    Trials by Status

    completed150%
    terminated150%

    Recent Activity

    0 active trials
    Showing 2 of 2
    completedphase_3

    A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects with Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.

    NCT03016013
    terminatedphase_2

    A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis

    NCT02882087

    Clinical Trials (2)

    Showing 2 of 2 trials
    NCT03016013Phase 3

    A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects with Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.

    Completed
    NCT02882087Phase 2

    A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis

    Terminated

    All 2 trials loaded

    Drug Details

    Intervention Type
    Varies by study
    Total Trials
    2